ESTRO 2025 - Abstract Book

S1882

Clinical - Urology

ESTRO 2025

Mean dose exposure to the rectum reduced by> 66% in the dose range between 60 and 70 Gy in the Patients with Hydrogel, while it was only > 7% in the dose range between 60Gy and 70Gy in the patients without hydrogel. No rectal or micturition symptoms occurred after PAE and also 3 months after EBRT. There was no GU toxicity ≥ Grade 3 and no GI Toxicity ≥ Grade 2 during radiotherapy.

Conclusion: Prostate artery embolization showed a short-term significant reduction in prostate volume prior to radiotherapy, which resulted in a significantly lower burden on the organs at risk and excellent tolerability of the therapy with a rapid fall in PSA. It should be considered a method in patients with initially large prostate volumes and/ or micturition problems before starting radiotherapy.

Keywords: prostate cancer, prostatic artery embolization,

300

Poster Discussion Health-related quality of life in patients treated for non-metastatic muscle-invasive bladder cancer: radical cystectomy vs bladder preserving therapy Katharina Brück 1,2 , Vera Atema 3 , Annemarie M. Leliveld 4 , Martine Franckena 5 , Richard P Meijer 6 , Michiel S van der Heijden 7 , A. Rogier Donders 8 , J. Alfred Witjes 9 , Carin A. Uyl-de Groot 10,11 , Lisa M.C. Hoogstraten 8,3 , Lambertus A. Kiemeney 8,9 , Joost L. Boormans 12 , Katja K.H. Aben 8,3 , Maarten C.C.M Hulshof 1,2 1 Radiation Oncology, Amsterdam UMC, Amsterdam, Netherlands. 2 Treatment and quality of life, Cancer Center Amsterdam, Amsterdam, Netherlands. 3 Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, Netherlands. 4 Urology, University Medical Center Groningen, Groningen, Netherlands. 5 Radiation Oncology, Erasmus MC, Rotterdam, Netherlands. 6 Oncological Urology, University Medical Center Utrecht, Utrecht, Netherlands. 7 Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. 8 Health Evidence, Radboud university medical center, Nijmegen, Netherlands. 9 Urology, Radboud university medical center, Nijmegen, Netherlands. 10 Health Technology Assessment, Institute for Medical Technology Assessment, Rotterdam, Netherlands. 11 Health Technology Assessment, Erasmus School of Health Policy & Management, Rotterdam, Netherlands. 12 Urology, Erasmus MC, Rotterdam, Netherlands Purpose/Objective: Patients with non-metastatic muscle-invasive bladder cancer (MIBC) can be treated with either radical cystectomy (RC) or bladder-preserving therapy (BPT). 1,2 Contemporary data on the impact of these treatments on health-related quality of life (HRQOL) are lacking. 3

Objective To compare HRQOL between patients treated with BPT and RC.